This study analyzed and compared diagnostic efficacy for liver cancers (including HCC and CCA) in serum AFP, AFP-L3%, PIVKA-II and recently published diagnostic models containing combined detection of these markers, as well as in serum CEA and CA19-9. This evidence concerns the gene CEACAM5 and hepatocellular carcinoma.